Atherosclerosis is a chronic inflammatory disease, and vaccination may be an attractive method to induce long lasting protection against endogenous factors that contribute to the development of atherosclerosis. We have shown that for example vaccination against modified LDL or interleukin-12 limits…

Can the conditioning paradigm be used for checkpoint inhibition cancer treatment?

For more information regarding ongoing research projects, please contact Prof. Johan Kuiper.

Promotores: Wim Jiskoot; Ferry Ossendorp

In this book liposomes are explored as delivery system for allergen-specific immunotherapy. Both cationic and anionic formulations are prepared with Bet v 1, one of the allergens in birch pollen.

Promotores: W. Jiskoot, F. Ossendorp

Strengthening a cancer patient's own immune system so that the body itself can better destroy cancer cells. This is at the heart of immunotherapy, the most promising progress in cancer treatment in recent years. In order to drive this development further, the Netherlands Cancer Institute-Antoni van…

Researchers from Leiden University Medical Center (LUMC) and Netherlands Cancer Institute (NKI) have discovered how specialised immune cells can detect and remove cancers that are ‘invisible’ to the conventional defence mechanisms of the immune system. Their work has been published in Nature. The findings…

In order to be able to develop effective medicine and treatments to prevent or cure autoimmune diseases or cancer we need to understand the mechanisms how they arise and what drives their course.Unravelling the fundamental molecular mechanisms influencing the onset and course of diseases such as allergies,…

This thesis focuses on using liposomes in two different treatment strategies; vaccination (or immunotherapy) and delivery of a small molecule, and in two different disease models; cancer and atherosclerosis.

Immunotherapies for cancer are an emerging class of therapeutic strategies which aim to treat cancer via augmentation of the immune system.

Promotores: J. Jonkers, K.E. de Visser

Poly(lactic-co-glycolic acid) (PLGA) particles have been extensively studied as biodegradable delivery system to improve the potency and safety of protein-based vaccines. In this study we analyzed how the size of PLGA particles, and hence their ability to be engulfed by dendritic cells (DC), affects…

In this PhD thesis, available data on the PK and/or PD of different targeted therapies, chemotherapy and immunotherapies obtained during both routine clinical practice and prospective clinical studies were analyzed.

The Therapeutic Immunomodulation Group is led by Prof. Johan Kuiper. In this group we aim to identify novel immunologic targets and apply immunotherapy to inhibit or even prevent the development of atherosclerosis.

The immune system plays a paradoxical role in the spread of breast cancer. Some immune cells contribute to metastasis, while other cells can be activated to strengthen the effect of chemotherapy. Kelly Kersten made this discovery in her PhD research. PhD defence 7 February.

With cancer, the immune system is a double-edged sword: it can attack tumour cells, but can also help them grow and spread. It is a question of harnessing it. This is what Professor Karin de Visser argued in her inaugural lecture on 15 November 2019.

When internist Christian Blank made his very first discovery, his field of immunotherapy was the underdog of cancer research. Now, over 20 years later, Blank has been appointed Professor By Special Appointment of Internal Medicine for his clinical research into immunotherapy and will give his inaugural…

Cancer is still one of the most common diseases in the world. What exactly is cancer and will we one day be able to cure everyone? In a video from the Universiteit van Nederland Noel de Miranda (Tumour Immunology, LUMC) tells you about his research on new treatments.

For effective cancer immunotherapy by vaccination, co-delivery of tumour antigens and adjuvants to dendritic cells and subsequent activation of antigen-specific cytotoxic T cells (CTLs) is crucial. In this study, a synthetic long peptide (SLP) harbouring the model CTL epitope SIINFEKL was encapsulated…

This joint Master with the Autonomous University of Barcelona will the equip you with the necessary competences to play a key role in the emerging field of transfusion medicine. The programme includes both transfusion of blood components and hematopoietic transplants, cellular and tissue therapy, and…

PhD defence

PhD defence

PhD defence

At the division of Biopharmaceutics, we aim to develop and test new therapeutic approaches to limit or even prevent the development of atherosclerosis in order to reduce the number of acute cardiovascular syndromes such as myocardial infarction or stroke.

In this project, we aim to obtain a quantitative understanding of the role of the immune system in tumor regression, of the role of tumor cell heterogeneity in cancer growth and of tumor cell migration properties.

Providing each cancer patient with the right treatment remains a challenge. Oncode Accelerator aims to change this by innovating the way we develop cancer treatments, thus ensuring the patient is at the heart of the process. Leiden University, the LUMC and other partners will implement this new way…

One of the main challenges in the development of an effective anti-cancer vaccine is the generation of an adequate and directed cellular immune response.

Bet v1, the major allergen in birch pollen, is one of the main causes of allergies such as asthma and rhino-conjunctivitis. Additionally it is the main cause of birch pollen allergy in humans.

This is an Erasmus+ International Credit Mobility project of Leiden University’s Faculty of Medicine with Kilimanjaro Christian Medical Center in Tanzania.

PhD defence

The Center for Interdisciplinary Placebo Studies Leiden (IPS) aims to advance the understanding of placebo and nocebo effects, their underlying mechanisms, and their potential applications in clinical practice. IPS consists of a group of interdisciplinary researchers working at Leiden University with…

The research within the Division of Cell Systems and Drug Safety, headed by Prof. Bob van de Water, is focused on novel therapeutic modalities and novel concepts in early drug discovery, in order to develop more effective and safer therapeutic strategies. We generate advanced cell and computational…

This joint two-year parttime Master's programme will equip you with the necessary competences to play a key role in the emerging field of transfusion medicine. Its current concept includes both the transfusion of classical blood components and hematopoietic transplants, but also cellular (e.g. as immunotherapy)…

PhD defence

Courses cover a broad range of relevant subjects and provide in-depth theoretical knowledge as well as training in practical skills and advanced research tools.

Lotje Zuur sometimes has to perform disfiguring operations. As a head and neck surgeon, she removes parts of the mouth, throat or face of people with cancer. Now a promising treatment may make such operations unnecessary. What would this mean for patients? This is what her inaugural speech on 19 September…

Ton Schumacher, professor by special appointment in Immunotechnology at the LUMC and group leader of Molecular Oncology and Immunology at the Netherlands Cancer Institute, has been awarded the NWO Stevin Prize. The Stevin Prize and the Spinoza Prize are the top scientific prizes in the Netherlands and…

On 10 September 2021, Professor Thorbald van Hall from the Department of Medical Oncology in the Leiden University Medical Center (LUMC) delivered his inaugural lecture ‘Tumour-immune interactions: control, escape and counterattack’. Van Hall used the opportunity to describe how - in a similar way to…

Three fundamental research projects at Leiden in physics, chemistry and medical science have received funding from the Dutch Research Council (NWO). They involve research on magnetic fields in the universe, the role of myeloid cells in cancer immunotherapy and the evolution of ancient proteins.

When the immune system attacks cancer, the tumour modifies itself to escape the immune reaction. Researchers at LUMC published on this subject in Nature on 28 June.

The ERC has awarded a Starting Grant to five promising researchers from Leiden. Two are from the Faculty of Social and Behavioural Sciences, one is from the Faculty of Humanities/Governance and Global Affairs, one from the LUMC and one from the Faculty of Science.

Physics and Engineering Approaches to Biomedicine and Pharmacology

Our immune system protects us against disease, but every now and then, something goes wrong: an enemy invades our bodies or our immune system attacks our own cells and we become ill. Doctors and researchers at the Leiden University Medical Center (LUMC) want to be able to manipulate the immune system…

The "Research Skills Assessment" aims to assess the academic research skills of the person doing the assignment. Successful evaluation of the assessment is a requirement for admission into the Creative Intelligence & Technology MSc program of Leiden University.

Do you want to make an impact in healthcare?

Sjaak Neefjes, professor of Chemical Immunology at the LUMC, has been awarded a Spinoza prize of 2.5 million euros. His colleague Ton Schumacher, professor of Immunotechnology affiliated with Leiden University, the LUMC and the Antoni van Leeuwenhoek cancer centre, has been awarded the Stevin prize,…

Professor of Cardiothoracic Surgery, in particular pulmonary surgery, Jerry Braun will give his inaugural lecture on Friday 23 September entitled ‘Out of countless millions’. Braun has been a professor and acting head of the LUMC’s Department of Cardiothoracic Surgery since January 2020. Covid meant…

Five consortia within the Perspectief programme that include Leiden researchers have received funding to start their research projects. These projects focus on (further) developing technological innovations, with societal and economic impact at their core.

Transferring poo from healthy donors to the intestines of chronically ill people has beneficial effects on these recipients’ gut bacteria, also in the longer term. This is the conclusion of research by the Leiden University Medical Center (LUMC) and the Netherlands Donor Feces Bank (NDFB).